GGrantIndex
Sort

130,381 grants matching hiv

HIV Vaccine Research and Development -Central Nervous System Studies

$1,017,672
National Institute Of Allergy And Infectious Diseases · Y01 · FY2014 · AI

Texas Repository for AIDS Neuropathogenesis Research

$1,017,626
Benjamin B. Gelman · University Of Texas Med Br Galveston · U01 · FY2011 · MH

Efficacy and cost of HAART DOT in methadone clinics

$1,017,554
Yeshiva University · R01 · FY2003 · DA

HIV Research Program in Thailand and Cambodia

$1,017,480
Kiat Ruxrungtham · Hiv-Nat, The Thai Red Cross Aids Rch Ctr · U19 · FY2006 · AI

Understanding the Role of the Host Response in HIVSIV Infection

$1,017,478
Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA

Scaling up HPTN 074: a Cluster Randomized Implementation Trial of an Evidence-based Intervention for Antiretroviral Therapy for PWID in Vietnam

$1,017,449
Vivian F. Go · Univ Of North Carolina Chapel Hill · R01 · FY2018 · DA

Vaccine Technologies

$1,017,293
Jeffrey Ulmer · Novartis Vaccines And Diagnostics, Inc. · P01 · FY2010 · AI

Adjustment Problems and Substance Use in 3 Generations

$1,017,258
Deborah M. Capaldi · Oregon Social Learning Center, Inc. · R01 · FY2007 · DA

Clinical Trials Program

$1,017,165
Timothy J Wilkin · Weill Medical Coll Of Cornell Univ · U54 · FY2020 · CA

NATURAL HISTORY OF MENOPAUSE IN HIV INFECTED DRUG USERS

$1,017,145
Montefiore Medical Center (Bronx, Ny) · R01 · FY2001 · DA

Opiate drug abuse and CNS vulnerability to HIV

$1,017,092
Kurt Francis Hauser · Virginia Commonwealth University · P01 · FY2009 · DA

AWI-Gen Phase 2: Genomic and environmental risk factors for cardiometabolic disease in Africans

$1,017,000
Michele Michele Ramsay · Wits Health Consortium (Pty), Ltd · U54 · FY2022 · HG

Reversing effector-to-memory transition at ARTi to impact the HIV reservoir towards ART-free control

$1,016,951
Francois J Villinger · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · AI

Therapeutic Disruption of HIV Transcription by HIV-1 Tat Protein-Degrading Molecules

$1,016,887
Susana T Valente · University Of Florida · R01 · FY2025 · AI

Faithful Response II: COVID-19 Rapid Test-to-Treat with African American Churches

$1,016,780
Jannette Yvonne Berkley-Patton · University Of Missouri Kansas City · U01 · FY2023 · MD

Inflammatory Mechanisms and Treatment Strategies for Atherosclerosis in HIV

$1,016,685
Steven Kyle Grinspoon · Massachusetts General Hospital · R01 · FY2012 · HL

Byramee Jeejeebhoy Medical College (BJMC), Pune, India: Clinical Trials Unit

$1,016,593
Amita Gupta · Johns Hopkins University · UM1 · FY2012 · AI

Biomarker Signatures of TB Infection in Young Children With and Without HIV

$1,016,533
Padmini Salgame · Rutgers Biomedical And Health Sciences · R01 · FY2025 · AI

Clonal Dynamics of HIV/SIV-specific T cells

$1,016,532
Daniel Cesar Douek · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI

HIV Database for HIV - AIDS Therapeutics and Microbicides

$1,016,287
Margaret Rush · Gryphon Scientific, Llc · N01 · FY2015 · AI

Ethical, Legal and Social Issues for Precision Medicine and Infectious Disease

$1,015,999
Gail Geller · Johns Hopkins University · RM1 · FY2016 · HG

MANAGEMENT OF INFORMATION RESOURCES ON THERAPEUTIC AGENTS FOR HIV AND OPPORTUNIS

$1,015,796
Margaret Andrews Rush · Gryphon Scientific, Llc · N01 · FY2010 · AI

Center for Prevention Implementation Methodology for Drug Abuse and HIV (Ce-PIM)

$1,015,767
C. Hendricks Brown · Northwestern University At Chicago · P30 · FY2019 · DA

FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORK

$1,015,636
University Of Miami School Of Medicine · U10 · FY2003 · DA

TICIPS: HIV/AIDS, Secondary Infections and Immune Modulation

$1,015,567
William Robert Folk · University Of Missouri-Columbia · U19 · FY2007 · AT